ClinicalTrials.gg
Not yet recruitingNCT07034781Updated Jun 24, 2025

A Study to Evaluate the Safety and Pharmacokinetics of Dapagliflozin, Linagliptin, and Metformin in Healthy Adults

A Phase 1 interventional study of Comparator 1 and Comparator 2 in Type2 Diabetes Mellitus, sponsored by AJU Pharm Co., Ltd.. Not yet recruiting at 1 site in South Korea. Open to participants aged 19 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-24.

Sponsored by AJU Pharm Co., Ltd. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Nov 2025, 1 year ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
19 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-20

Among 571 studies in Diabetes Mellitus, Type 2 with a site in Korea, Republic of — 70 open to participants now, 84 under way, 26 of them phase 3. Diabetes Mellitus, Type 2 · Korea, Republic of.

Planned enrollment
364th of 493
50 · median 174
Started
2025
with 20 others
Phase 1
95 of 571
8 open now
Primary completion
2025-11
later than 18 of 83 live
Registered
522nd of 571
by date

Among the 571 studies in Diabetes Mellitus, Type 2 with a site in Korea, Republic of, this one is the 364th largest by planned enrollment of the 493 interventional ones that give a count, is one of 21 that started in 2025, is one of 95 in phase 1, reaches primary completion later than 18 of the 83 other live ones, and was the 522nd registered.

Diabetes Mellitus, Type 2

10,402 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

70 of the 571 studies in Diabetes Mellitus, Type 2 with a site in Korea, Republic of are open now. Recruiting first, the newest first:

65 more — sign in →

All 70 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 381 (43%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 19 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 571 studies in Diabetes Mellitus, Type 2 with a site in Korea, Republic of, or all of them as a file.
02

Study summary

To Evaluate the Safety and Pharmacokinetics of Dapagliflozin, Linagliptin, and Metformin in Healthy Adults

03

Conditions studied

  • Type2 Diabetes Mellitus
04

Who can participate

Ages eligible
19 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult volunteers aged 19 to 50 years at the time of screening.
  • (BMI) between 18.0 and 30.0 kg/m², inclusive.

    • Male subjects must weigh ≥50 kg.
    • Female subjects must weigh ≥45 kg.
  • No congenital or chronic diseases requiring treatment, based on medical history and physical examination.
  • Clinically acceptable results from laboratory tests (e.g., hematology, biochemistry, serology, urinalysis) and (ECG) at screening, as determined by the investigator.
  • Willing to use medically accepted (excluding hormonal methods) from the first dose until 50 days after the last dose, and agrees not to donate sperm or eggs during this period.
  • Able and willing to provide written after receiving a full explanation of the study.

Exclusion criteria

Exclusion Criteria:

  • Use of drugs known to induce or inhibit drug-metabolizing enzymes within 30 days prior to the first dose, or any medication likely to interfere with the study within 10 days prior to dosing.
  • Participation in any clinical trial involving products within 6 months prior to the first dose.
  • Whole blood donation within 8 weeks, or component blood donation within 2 weeks prior to the first dose.
  • History of gastrointestinal surgery that may affect drug absorption (excluding appendectomy and hernia repair).
  • History of excessive alcohol consumption within 1 month prior to the first dose:

    • >21 drinks/week for males, >14 drinks/week for females (1 drink = 50 mL soju, 30 mL whiskey, or 250 mL beer)
  • Known to any component of the investigational product.
  • renal, hepatic, cardiovascular, respiratory, metabolic, or infectious diseases, including but not limited to:

    • Moderate to severe renal impairment ( or \<45 mL/min)
    • Dialysis
    • Acute or unstable heart failure
    • Acute myocardial infarction, septicemia, or shock
    • Type 1 diabetes, metabolic acidosis, or history of diabetic ketoacidosis
    • Major surgery planned during the study (except minor procedures not affecting food or fluid intake)
    • Severe infections, trauma, or nutritional deficiencies
  • Positive pregnancy test or currently breastfeeding (for female subjects).
  • History of significant psychiatric illness.
  • Determined by the investigator to be unsuitable for the study for any other reason.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Group A

    Two-period, single-dose, crossover study

    Drug: Comparator 1 · Drug: Comparator 2 · Drug: Test Drug

  • Experimental
    Group B

    Two-period, single-dose, crossover study (reversed order)

    Drug: Comparator 1 · Drug: Comparator 2 · Drug: Test Drug

Interventions

  • DrugComparator 1

    Dapagliflozin 10mg + Linagliptin 5mg

  • DrugComparator 2

    Metformin 1000mg

  • DrugTest Drug

    Fixed-dose combination tablet (AJU-A53)

06

What researchers measure

Primary outcomes

  1. Cmax of Dapagliflozin

    To assess the maximum observed plasma concentration (Cmax) of Dapagliflozin

    Time frame: 0 hour ~ 48 hour after drug administration

  2. AUCt of Dapagliflozin

    To assess the area under the plasma concentration-time curve from time 0 to the last measurable concentration (AUCt) of Dapagliflozin

    Time frame: 0 hour ~ 48 hour after drug administration

  3. Cmax of Linagliptin

    To assess the maximum observed plasma concentration (Cmax) of Linagliptin

    Time frame: 0 hour ~ 72 hour after drug administration

  4. AUCt of Linagliptin

    To assess the area under the plasma concentration-time curve from time 0 to the last measurable concentration (AUCt) of Linagliptin

    Time frame: 0 hour ~ 72 hour after drug administration

  5. Cmax of Metformin

    To assess the maximum observed plasma concentration (Cmax) of Metformin

    Time frame: 0 hour ~ 48 hour after drug administration

  6. AUCt of Metformin

    To assess the area under the plasma concentration-time curve from time 0 to the last measurable concentration (AUCt) of Metformin

    Time frame: 0 hour ~ 48 hour after drug administration

07

Study locations

1 site
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2025; primary completion for Nov 2025, 3 months later.

Of 454 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's planned 3 months is below that.

Counting every sponsor, half of 516 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2025
First posted
Jun 24, 2025
StartEst.
Aug 2025
Primary completionEst.
Nov 2025
CompletionEst.
Nov 2025
Last update
Jun 24, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07034781
Responsible party
Sponsor
First posted
Jun 24, 2025
Start date
Aug 2025 (estimated)
Primary completion
Nov 2025 (estimated)
Completion
Nov 2025 (estimated)
Last update
Jun 24, 2025

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion